Search results for "coagulants"

showing 10 items of 248 documents

Dabigatran: A new oral anticoagulant. Guidelines to follow in oral surgery procedures. A systematic review of the literature.

2015

Background Dabigatran is a newly commercialized drug that is replacing other anticoagulants in the prevention of venous thromboembolism, stroke and systemic arterial valve embolism. It acts directly on thrombin presenting in a dynamic and predictable way, which does not require monitoring these patients. Therefore, we consider the need to assess whether their use increases the risk of bleeding involved before any dental treatment. Material and Methods We performed a systematic review with a bibliographic search in PubMed/Medline along with the Cochrane Library. We excluded articles dealing with all anticoagulants other than dabigatran, and works about surgical treatments in anatomical locat…

medicine.medical_specialtyOral Surgical ProceduresPsychological interventionMEDLINEAdministration OralReviewCochrane LibraryPostoperative Hemorrhagelaw.inventionDabigatran03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicineHumansIntensive care medicineGeneral DentistryStrokebusiness.industryAnticoagulants030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseMedically compromised patients in DentistrySurgeryDabigatranClinical trialOtorhinolaryngologyEmbolism030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASSurgerybusinessmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Extractions without eliminating anticoagulant treatment: A literature review

2010

To establish whether there is a high enough risk of bleeding in patients who take oral anticoagulants, such that it would justify not using oral anticoagulants when performing a dental extraction, as well as if the reason for and anatomical location of the extraction increases such risk. Study We performed a bibliographic search in order to carry out a meta-analytic study using descriptive statistics. We compiled a sample of 1194 patients from the articles selected. Of these patients, a total of 2392 simple, serial surgical extractions were performed; none of the patients interrupted their anticoagulant treatment with warfarin sodium. Of the sample, 83 patients presented a certain degree of…

medicine.medical_specialtyPeriodontal pathologybusiness.industryContraindicationsmedicine.medical_treatmentIncidence (epidemiology)AnticoagulantsDentistrySoft tissue:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgeryOtorhinolaryngologyDental extractionAnticoagulant therapyMaxillaHemostasisTooth ExtractionUNESCO::CIENCIAS MÉDICASHumansMedicineSurgeryPericoronitisbusinessGeneral DentistryMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias an…

2012

Hypertension is the most common cardiovascular disorder and atrial fibrillation is the most common clinically significant arrhythmia. Both these conditions frequently coexist and their prevalence increases rapidly with aging. There are different risk factors and clinical conditions predisposing to the development of atrial fibrillation, but due its high prevalence, hypertension is still the main risk factor for the development of atrial fibrillation. Several pathophysiologic mechanisms (such as structural changes, neurohormonal activation, fibrosis, atherosclerosis, etc.) have been advocated to explain the onset of atrial fibrillation. The presence of atrial fibrillation per se increases th…

medicine.medical_specialtyPhysiologymacromolecular substancesFibrosisRisk FactorsCardiovascular DisorderInternal medicineThromboembolismAtrial FibrillationInternal MedicinemedicineHumanscardiovascular diseasesRisk factorStrokeSocieties Medicalbusiness.industryWarfarinAtrial fibrillationHypertension atrial fibrillation anticoagulants antihypertensive treatmentMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREmedicine.diseaseThrombosisEuropeBlood pressureHypertensionCardiologyCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of hypertension
researchProduct

Substantial Reduction of Platelet Adhesion by Heparin-Coated Stents

2001

Although optimized antiplatelet medication has improved the clinical outcome after coronary stenting, vessel occlusion and restenosis still remain a relevant clinical problem. Platelets play a key role in this process. Therefore, the authors compared the platelet adhesion on different stent surface modifications (electropolished without coating or coated with carbon, carbon and additional heparin, silicon carbide, or heparin alone) to investigate their role in reducing platelet adhesion. All stents and additional stainless steel plates were incubated in heparinized whole blood with radiolabeled platelets. After washing the stents and plates four times, radioactivity caused by the adhesion o…

medicine.medical_specialtyPlatelet adhesionmedicine.medical_treatmentIn Vitro Techniquesengineering.materialPlatelet AdhesivenessRestenosisCoatingmedicineHumansRadiology Nuclear Medicine and imagingPlateletWhole bloodHeparinbusiness.industryGraft Occlusion VascularAnticoagulantsStentHeparinAdhesionequipment and suppliesmedicine.diseaseSurgeryengineeringStentsCardiology and Cardiovascular MedicinebusinessBiomedical engineeringmedicine.drugJournal of Interventional Cardiology
researchProduct

Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents

2021

Thrombosis and neoplasms are strictly linked, and the diagnosis of a malignancy is a relevant risk factor for venous thromboembolism (VTE). In particular, between gammopathies, the VTE risk is known to be increased in both monoclonal gammopathy of uncertain significance and in multiple myeloma, with a 3- and 9-fold increase respectively, when compared to the general population. The risk appears to be further increased in patients treated with immunomodulating drugs, such as thalidomide, especially when in combination with dexamethasone or conventional cytotoxic chemotherapies, and lenalidomide. In 2008 the International Myeloma Working Group put out thrombosis prophylaxis recommendations fo…

medicine.medical_specialtyPopulationAntineoplastic Agents030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineFibrinolytic AgentsRisk FactorsInternal medicinemedicineHumansImmunologic FactorsRisk factoreducationMultiple myelomaLenalidomideeducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryWarfarinAnticoagulantsVenous ThromboembolismGeneral MedicineEvidence-based medicinemedicine.diseaseThrombosisPrevention and controlThalidomideTreatment OutcomeMultiple MyelomabusinessProteasome Inhibitorsmedicine.drugPanminerva Medica
researchProduct

Predicting Venous Thromboembolism in Primary Care

2020

medicine.medical_specialtyPrimary Health Carebusiness.industryPrimary health careMEDLINEAnticoagulantsVenous ThromboembolismHematologyPrimary careRisk FactorsmedicineHumansIntensive care medicinebusinessVenous thromboembolismThrombosis and Haemostasis
researchProduct

The changing landscape of thromboprophylaxis for atrial fibrillation: insights from the ISPAF-2 survey

2018

Atrial fibrillation is the most common sustained cardiac dysrhythmia. It represents a major public health problem due to increased mortality risk, reduced quality of life, and increased health costs [1, 2]. The prevalence of nonvalvular atrial fibrillation (AF) continues to increase worldwide, largely affecting the elderly, but also occurring in younger patients as a result of structural heart disease, autonomic imbalance, genetic abnormality, or previous cardiac surgery [3]. The rise in prevalence of AF is largely due to the increasing age of the population. About 1–2% of the total population is affected by AF, but the prevalence of this condition rises to ≈ 10% in individuals aged > 75…

medicine.medical_specialtySettore MED/09 - Medicina Internabusiness.industryMEDLINEAtrial fibrillaztion - Anticoagulants - NOACs - DOACsAnticoagulantsAtrial fibrillation030204 cardiovascular system & hematologymedicine.diseaseStroke03 medical and health sciences0302 clinical medicineItalySurveys and QuestionnairesAtrial FibrillationEmergency MedicineInternal MedicinemedicineHumans030212 general & internal medicineIntensive care medicinebusinessStroke
researchProduct

Health literacy of patients on oral anticoagulation treatment- individual and social determinants and effect on health and treatment outcomes

2021

Abstract Background Assessment health literacy in people with cardiovascular health problems would facilitate the development of appropriate health strategies for the care and reduction of complications associated with oral anticoagulation therapy. Aim: To evaluate the relationship between health literacy and health and treatment outcomes (concordance with oral anticoagulants, Normalized Ratio control and occurrence of complications) in patients with cardiovascular pathology. Methods Observational, analytic and cross-sectional study carried out on 252 patients with cardiovascular pathology (atrial fibrillation, flutter or valve prosthesis), aged 50–85 years, accessing primary care services …

medicine.medical_specialtySocial Determinants of HealthAdministration OralHealth literacy030204 cardiovascular system & hematologyRT1117 Public Health and Health ServicesTreatment adherence and compliance03 medical and health sciences0302 clinical medicineRA0421Atrial FibrillationEpidemiologySelf-managementmedicineHumansSalutAlfabetització030212 general & internal medicineSocial determinants of healthPublic Environmental & Occupational HealthDrug-related side effects and adverse reactionPolypharmacyAcenocoumarolScience & Technologybusiness.industryAcenocoumarolPublic healthPublic Health Environmental and Occupational HealthHealth literacyAnticoagulantsCAREHealth servicesCross-Sectional StudiesTreatment OutcomeSpainEmergency medicineHEART-FAILUREObservational studyPublic HealthPublic aspects of medicineRA1-1270BiostatisticsbusinessLife Sciences & BiomedicineResearch Articlemedicine.drugBMC Public Health
researchProduct

European guidelines on perioperative venous thromboembolism prophylaxis:Day surgery and fast-track surgery

2017

: In recent years, day surgery and fast-track surgery have experienced a continuous increase in volume. Many procedures are now performed on an outpatient protocol, including general, orthopaedic, oncological, reconstructive or vascular surgery. The management of these patients is safe, but the incidence of venous thromboembolism in this population remains unknown. Several risk factors can be identified and stratified derived from studies of inpatient surgical management (e.g. Caprini score). Recommendations for thromboprophylaxis should be tailored from the assessment of both personal and procedure-related risk factors, although with a lack of evidence for application in outpatient managem…

medicine.medical_specialtyTime FactorsPopulationMEDLINEHemorrhage030204 cardiovascular system & hematologyPerioperative Care03 medical and health sciencesPostoperative Complications0302 clinical medicineAnesthesiologyRisk FactorsJournal ArticleHumansMedicinemedia_common.cataloged_instanceEuropean UnionEuropean unioneducationEarly AmbulationSocieties Medicalmedia_common030222 orthopedicseducation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)AnticoagulantsVenous ThromboembolismPerioperativeHeparin Low-Molecular-WeightVascular surgerySurgeryAnesthesiology and Pain MedicineAmbulatory Surgical ProceduresFast track surgerybusinessVenous thromboembolism
researchProduct

How should we determine length of anticoagulation after proximal deep vein thrombosis of the lower limbs?

2009

The current approach for deciding the duration of vitamin K antagonist (VKA) treatment after an episode of venous thrombo-embolism (VTE) is mainly based on the characteristic of the index event (3 months or longer in case of unknown/persistent risk factors, 3 months or less in case of removable causes). However, the length of anticoagulation should be tailored on the patient's risk for recurrent thrombosis as well as for bleeding, but such 'time for decision' is often unclear and the optimal duration of VKA remains debatable. The presence of persistent residual vein thrombosis and increased D-dimer levels after stopping therapy are predictors for recurrent deep vein thrombosis (DVT). Manage…

medicine.medical_specialtyTime FactorsVitamin Kmedicine.drug_classDeep veinRisk AssessmentDrug Administration ScheduleRecurrent deep vein thrombosisSettore MED/15 - Malattie Del SangueFibrin Fibrinogen Degradation ProductsFibrinolytic AgentsRecurrenceNeoplasmsmedicineHumansVenous ThrombosisFirst episodebusiness.industryVascular diseaseAnticoagulantVitaminsHematologyVitamin K antagonistmedicine.diseaseThrombosisduration anticoagulants venous thromboembolismSurgeryVenous thrombosismedicine.anatomical_structurebusinessBiomarkersBritish Journal of Haematology
researchProduct